Geneuro SA - Asset Resilience Ratio
Geneuro SA (GNRO) has an Asset Resilience Ratio of 28.72% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Geneuro SA total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2023)
This chart shows how Geneuro SA's Asset Resilience Ratio has changed over time. See net assets of Geneuro SA for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Geneuro SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Geneuro SA worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €1.83 Million | 28.72% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €1.83 Million | 28.72% |
Asset Resilience Insights
- Very High Liquidity: Geneuro SA maintains exceptional liquid asset reserves at 28.72% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Geneuro SA Industry Peers by Asset Resilience Ratio
Compare Geneuro SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merus BV
NASDAQ:MRUS |
Biotechnology | 29.69% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 30.29% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Savara Inc
NASDAQ:SVRA |
Biotechnology | 76.71% |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871 |
Biotechnology | 9.59% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for Geneuro SA (2012–2023)
The table below shows the annual Asset Resilience Ratio data for Geneuro SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 28.72% | €1.83 Million ≈ $2.14 Million |
€6.36 Million ≈ $7.44 Million |
-20.25pp |
| 2022-12-31 | 48.98% | €5.59 Million ≈ $6.54 Million |
€11.42 Million ≈ $13.35 Million |
+4.86pp |
| 2021-12-31 | 44.11% | €5.48 Million ≈ $6.41 Million |
€12.42 Million ≈ $14.52 Million |
-21.46pp |
| 2020-12-31 | 65.57% | €6.84 Million ≈ $8.00 Million |
€10.44 Million ≈ $12.20 Million |
+1.80pp |
| 2019-12-31 | 63.77% | €5.93 Million ≈ $6.93 Million |
€9.30 Million ≈ $10.87 Million |
+14.08pp |
| 2014-12-31 | 49.69% | €4.50 Million ≈ $5.26 Million |
€9.06 Million ≈ $10.59 Million |
+1.50pp |
| 2013-12-31 | 48.19% | €2.02 Million ≈ $2.36 Million |
€4.20 Million ≈ $4.91 Million |
+45.28pp |
| 2012-12-31 | 2.92% | €150.00K ≈ $175.37K |
€5.14 Million ≈ $6.01 Million |
-- |
About Geneuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsy… Read more